Smoking Cessation - The global smoking cessation market is forecast to reach $4.4bn in 2023

 

 

The global smoking cessation market is going from strength to strength, globally, with ever increasing products coming to the market both prescription and over—the-counter (OTC). Most notable are the range of Vaping (e-cigarettes / smokeless cigarettes) products, a market which was estimated to be worth over $3bn across both 2013 and 2014. Where has this market come from?

 

Smoking patterns have shifted with many smokers quitting, or attempting to quit;

Prevalence of US Adult (18+) Smokers (%)

Year

1990

1995

2000

2005

2010

2015(e)

2020(e)

 

Male

28.4%

26.9%

25.7%

22.7%

21.5%

20.5%

17.1%

 

Female

22.8%

21.9%

21.0%

19.1%

17.3%

15.3%

14.1%

 

Overall %

25.5%

24.4%

23.3%

20.9%

19.3%

17.8%

15.6%

 

GMR Data / CDC 2015

 

As we can see from the table above the amount of adult Americans that smoke has reduced significantly from 25.5% in 1990 to 17.8% by the end of this year; that’s 46.3m (1990) to 36.5m (2015). So the number of smokers, in the US, has reduced by around 10m in 25 years.

The US health authority – the Centers’ for Disease Control & Prevention (CDC) indicate that the percentage of adult (daily) cigarette smokers who stopped smoking for more than 1 day in 2010, because they were trying to quit, was 42.7% of all adult smokers;

48.5% of smokers aged 18–24 years                   

46.8% of smokers aged 25–44 years                   

38.8% of smokers aged 45–64 years                   

34.6% of smokers aged 65 years or older            

 

In terms of smoking cessation what we have is 2 distinct groups of people;

  • those that want to quit and have been succesful
  • those that want to quit and have failed (so far)

 

Both these groups offer value to the smoking cessation market; particularly the latter as they are recurrent users of smoking cessation products. Nicoderm and Habitrol are the primary Nicotine Replacement Therapy (NRT) products on the market, accounting for over 80% of the global NRT market revenue in 2013. Bupropion and Varenicline are the major products in the prescription drug segment of the smoking cessation market. 

GMR Data’s smoking cessation report outlines the key factors affecting the market to 2023. GMR Data forecast that the global e-cigarette market will reach $3bn across 2013, up from an estimated $1.5bn in 2012. GMR Data estimate that the global e-cigarette market will reach $15bn by 2023.

GMR Data’s report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.

The report, similarly to all GMR Data reports, includes exclusive interviews with industry participants. In this report there are 3 exclusive interview transcripts from representatives from GlaxoSmithKline, Elder Pharma and Pfizer.

 

For more details on the pharmaceutical reports that GMR Data publish head to

http://gmrdata.com/pharmaceutical-reports/the-global-smoking-cessation-market-2013-2023.html